Edition:
India

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

10.05USD
13 Dec 2017
Change (% chg)

$0.20 (+2.03%)
Prev Close
$9.85
Open
$9.82
Day's High
$10.05
Day's Low
$9.70
Volume
13,105
Avg. Vol
30,769
52-wk High
$15.75
52-wk Low
$5.48

Chart for

About

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein... (more)

Overall

Beta: --
Market Cap(Mil.): $70.42
Shares Outstanding(Mil.): 9.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Ra Capital Management says it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 mln

* Ra Capital Management says ‍​on Oct 12, it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 million - SEC Filing

14 Nov 2017

BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍​

* Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing‍​ Source text - http://bit.ly/2xTHJJO Further company coverage:

21 Oct 2017

BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck

* Kalvista Pharmaceuticals announces collaboration with Merck

10 Oct 2017

BRIEF-KalVista Pharmaceuticals reports Q1 loss per share of $0.51

* KalVista pharmaceuticals reports fiscal first quarter results

14 Sep 2017

BRIEF-Kalvista Pharmaceuticals reports Q4 loss per share $0.43

* Kalvista Pharmaceuticals provides operational update and reports fiscal fourth quarter and full year financial results

28 Jul 2017

BRIEF-Kalvista Pharmaceuticals enters into an at-market sales agreement with BTIG

* Kalvista Pharmaceuticals Inc - on July 13, 2017 co entered into an at--market sales agreement with BTIG, LLC

14 Jul 2017

Earnings vs. Estimates